- Email: [email protected]
Oncology Signaling – Signal a new era in cancer research
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
ONSIG2_proof ■ 7 October 2017 ■ 1/1
Oncology Signaling xxx (2017) 1
Contents lists available at ScienceDirect
Oncology Signaling journal homepage: http://www.keaipublishing.com/ONSIG
Q3
Regulation of c-Myc and NBS1 by ionizing radiation in glioblastoma cells Cancer signaling has become fundamental in our understanding and treatment of cancer and it will become essential in the development of precision medicine for cancer. Indeed, genome sequencing has revealed significant abnormalities in signal transduction pathways in virtually all types of cancer. Targeted cancer therapies that inhibit specific signaling pathways altered in cancer are now used to treat cancer patients. Unfortunately, these therapies often fail to cure and worse still cancer cells become resistant to these therapies. There is a need for better understanding on how signaling is dysregulated in cancer, and how signaling pathways adapt to changes in the tumor microenvironment and to therapeutic treatments. To address these challenges in cancer research, we have launched a new journal Oncology Signaling. This journal will tackle a broad scope of relevant issues in cancer signaling in basic sciences, discovery based, clinical and translational research. Topics could range from the role of receptor and non-receptor protein kinases, lipid mediators, nitric oxide signaling and ion channels, regulation of secondary messengers, G-protein coupled receptors, guanine nucleotide regulatory proteins, bioinformatic studies relevant to cell signaling, and microenvironmental signals. Research describing the mechanisms of action of signaling pathways in cancer as it relates to current or new treatments will be a focus. Authors should address how their research results differ from previous reported studies. The submission could be original research study or a relevant review of current advances in oncology signaling. Short communications or a letter to editor would also be acceptable for expanding upon recently published research. Manuscripts with emerging themes, challenges and ideas in oncology signaling will be strongly considered for this journal. We will also emphasize method based manuscripts that describe relevant and emerging techniques or technology in cancer signaling research. It is the goal of this journal to be the home for cutting edge signal transduction research as it relates to cancer. Some journals might have a focus on signal transduction whereas others might focus on aspects of cancer research but this is the first journal to focus on oncology signaling exclusively. We will be broad and
innovative in our point of view on cancer signaling and will be a forum for new ideas, challenges, technologies, techniques and model systems. A quality peer-review process will be followed to ensure impactful papers and leaders in the field will be enlisted to give opinions, and commentary on emerging areas in cancer signaling. We welcome the scientific community to embrace this new journal Oncology Signaling to give a focus to this fundamental and translational research area, and to emphasize the significance of signal transduction to all cancers. I look forward to this journal becoming a trusted resource in cancer signaling and propelling the research field forward in our understanding and treatment of cancer. To this end, the journal will be open access and will be part of the ScienceDirect platform to ensure a broad readership of our publications.
We hope to signal a new era in cancer research. Yours Sincerely, Spence B. Gibson, Editor-in-Chief Q2 University of Manitoba, Departments of Biochemistry and Medical Q1 Genetics and Immunology, Winnipeg, Manitoba, Canada E-mail address: [email protected]. 5 July 2017 Available online xxx
Peer review under responsibility of KeAi Communications Co., Ltd. https://doi.org/10.1016/j.onsig.2017.09.001 2542-5633/© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Gibson SB, Regulation of c-Myc and NBS1 by ionizing radiation in glioblastoma cells, Oncology Signaling (2017), https://doi.org/10.1016/j.onsig.2017.09.001
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99
ONSIG2_proof ■ 7 October 2017 ■ 1/1
Oncology Signaling xxx (2017) 1
Contents lists available at ScienceDirect
Oncology Signaling journal homepage: http://www.keaipublishing.com/ONSIG
Q3
Regulation of c-Myc and NBS1 by ionizing radiation in glioblastoma cells Cancer signaling has become fundamental in our understanding and treatment of cancer and it will become essential in the development of precision medicine for cancer. Indeed, genome sequencing has revealed significant abnormalities in signal transduction pathways in virtually all types of cancer. Targeted cancer therapies that inhibit specific signaling pathways altered in cancer are now used to treat cancer patients. Unfortunately, these therapies often fail to cure and worse still cancer cells become resistant to these therapies. There is a need for better understanding on how signaling is dysregulated in cancer, and how signaling pathways adapt to changes in the tumor microenvironment and to therapeutic treatments. To address these challenges in cancer research, we have launched a new journal Oncology Signaling. This journal will tackle a broad scope of relevant issues in cancer signaling in basic sciences, discovery based, clinical and translational research. Topics could range from the role of receptor and non-receptor protein kinases, lipid mediators, nitric oxide signaling and ion channels, regulation of secondary messengers, G-protein coupled receptors, guanine nucleotide regulatory proteins, bioinformatic studies relevant to cell signaling, and microenvironmental signals. Research describing the mechanisms of action of signaling pathways in cancer as it relates to current or new treatments will be a focus. Authors should address how their research results differ from previous reported studies. The submission could be original research study or a relevant review of current advances in oncology signaling. Short communications or a letter to editor would also be acceptable for expanding upon recently published research. Manuscripts with emerging themes, challenges and ideas in oncology signaling will be strongly considered for this journal. We will also emphasize method based manuscripts that describe relevant and emerging techniques or technology in cancer signaling research. It is the goal of this journal to be the home for cutting edge signal transduction research as it relates to cancer. Some journals might have a focus on signal transduction whereas others might focus on aspects of cancer research but this is the first journal to focus on oncology signaling exclusively. We will be broad and
innovative in our point of view on cancer signaling and will be a forum for new ideas, challenges, technologies, techniques and model systems. A quality peer-review process will be followed to ensure impactful papers and leaders in the field will be enlisted to give opinions, and commentary on emerging areas in cancer signaling. We welcome the scientific community to embrace this new journal Oncology Signaling to give a focus to this fundamental and translational research area, and to emphasize the significance of signal transduction to all cancers. I look forward to this journal becoming a trusted resource in cancer signaling and propelling the research field forward in our understanding and treatment of cancer. To this end, the journal will be open access and will be part of the ScienceDirect platform to ensure a broad readership of our publications.
We hope to signal a new era in cancer research. Yours Sincerely, Spence B. Gibson, Editor-in-Chief Q2 University of Manitoba, Departments of Biochemistry and Medical Q1 Genetics and Immunology, Winnipeg, Manitoba, Canada E-mail address: [email protected]. 5 July 2017 Available online xxx
Peer review under responsibility of KeAi Communications Co., Ltd. https://doi.org/10.1016/j.onsig.2017.09.001 2542-5633/© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Gibson SB, Regulation of c-Myc and NBS1 by ionizing radiation in glioblastoma cells, Oncology Signaling (2017), https://doi.org/10.1016/j.onsig.2017.09.001
46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99